{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:29:52Z","timestamp":1793996992281,"version":"4.8.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Ethics"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Despite progress in antiretroviral therapy (ART), an effective cure for HIV remains out of reach. End-of-life (EOL) research studies involving individuals with a prognosis of six months or less offers an opportunity to advance cure science but has so far been limited to observational designs focused on HIV reservoirs. As interventional approaches at the EOL are now being considered, it is essential to assess their acceptability before moving forward. Understanding how long-term survivors (LTS) of HIV perceive these potential interventions, along with their motivations and ethical considerations, is critical to guiding the design of future EOL-HIV interventional research.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted in-depth qualitative interviews with 16 LTS of HIV from across regions in United States to examine their views on hypothetical interventional HIV cure research at the EOL. To ensure representation, we recruited participants through community-based organizations and HIV cure collaboratories using purposive-sampling. We conducted interviews via secure teleconferencing, transcribed the recordings, and used inductive thematic analysis to identify key themes related to motivations, acceptability, and ethical considerations surrounding interventional EOL HIV cure research.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Participants viewed hypothetical interventional HIV cure research at the EOL as a way to contribute to science, despite expecting no personal benefit. They prioritized autonomy and informed-choice in ethical participation. Many supported latency-reversing agents but raised safety concerns; in contrast, they viewed block-and-lock strategies as promising and less risky. Participants generally welcomed immune-based approaches, though some questioned their suitability for older adults near the EOL. LTS found cell and gene-based interventions innovative but expressed caution about safety and feasibility. While they valued the scientific potential of combination strategies, they noted their complexity and burden. Opinions on analytical treatment interruptions were mixed and depended on ethical safeguards, including medical oversight and reversibility. Willingness to participate in hypothetical HIV cure research at the EOL reflected individual health status, perceived burden, and personal values.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>LTS are willing to engage in interventional EOL HIV cure research but emphasize the importance of ethical safeguards and participant autonomy. As HIV cure research progresses, integrating LTS perspectives is critical to designing feasible, ethical, and scientifically impactful interventional studies at EOL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12910-025-01253-x","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T05:50:42Z","timestamp":1755928242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Motivations, acceptability and ethical considerations for interventional HIV cure research at the end of life: perspectives from long-term survivors of HIV in the United States"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8964-1853","authenticated-orcid":false,"given":"Ali","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Swaitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel O.","family":"Ndukwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris H.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Solso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Dullano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Kaytes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3603-1733","authenticated-orcid":false,"given":"Davey","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Deiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9927-0849","authenticated-orcid":false,"given":"Sara","family":"Gianella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3458-1539","authenticated-orcid":false,"given":"Karine","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"12","key":"1253_CR1","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","volume":"27","author":"SG Deeks","year":"2021","unstructured":"Deeks SG, Archin N, Cannon P, et al. Research priorities for an HIV cure: international AIDS society global scientific strategy 2021. Nat Med. 2021;27(12):2085\u201398. https:\/\/doi.org\/10.1038\/s41591-021-01590-5.","journal-title":"Nat Med"},{"key":"1253_CR2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2024.0117","author":"A Ahmed","year":"2025","unstructured":"Ahmed A, Taylor J, Diunugala SD, et al. Sometimes they exclude Us because of our Age-That\u2019s not right: perceptions of HIV cure research among diverse Long-Term survivors in the united States. AIDS Res Hum Retroviruses. 2025. https:\/\/doi.org\/10.1089\/aid.2024.0117.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"1253_CR3","unstructured":"The Wells Project, Long-Term Survivors of HIV. 2023. Available from: https:\/\/www.thewellproject.org\/hiv-information\/long-term-survivors-hivAccessed; 16 Mar 2025."},{"issue":"10","key":"1253_CR4","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1080\/09540121.2023.2206095","volume":"35","author":"CA Nkwonta","year":"2023","unstructured":"Nkwonta CA, Brown MJ, James T, et al. Gender and coping with HIV: a qualitative study of older childhood sexual abuse survivors living with HIV. AIDS Care. 2023;35(10):1465\u201371. https:\/\/doi.org\/10.1080\/09540121.2023.2206095.","journal-title":"AIDS Care"},{"issue":"3","key":"1253_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/infdis\/162.3.638","volume":"162","author":"RB Roberts","year":"1990","unstructured":"Roberts RB, Jurica K, Meyer WA 3, et al. A phase 1 study of ribavirin in human immunodeficiency virus-infected patients. J Infect Dis. 1990;162(3):638\u201342. https:\/\/doi.org\/10.1093\/infdis\/162.3.638.","journal-title":"J Infect Dis"},{"issue":"1","key":"1253_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-2478(93)90060-f","volume":"36","author":"RB Stricker","year":"1993","unstructured":"Stricker RB, Zhu YS, Elswood BF, et al. Pilot study of topical Dinitrochlorobenzene (DNCB) in human immunodeficiency virus infection. Immunol Lett. 1993;36(1):1\u20136. https:\/\/doi.org\/10.1016\/0165-2478(93)90060-f.","journal-title":"Immunol Lett"},{"issue":"4","key":"1253_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/nejm198707233170401","volume":"317","author":"MA Fischl","year":"1987","unstructured":"Fischl MA, Richman DD, Grieco MH, et al. The efficacy of Azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):185\u201391. https:\/\/doi.org\/10.1056\/nejm198707233170401.","journal-title":"N Engl J Med"},{"issue":"10","key":"1253_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","volume":"21","author":"RJ Landovitz","year":"2023","unstructured":"Landovitz RJ, Scott H, Deeks SG. Prevention, treatment and cure of HIV infection. Nat Rev Microbiol. 2023;21(10):657\u201370. https:\/\/doi.org\/10.1038\/s41579-023-00914-1.","journal-title":"Nat Rev Microbiol"},{"issue":"27","key":"1253_CR9","doi-asserted-by":"publisher","first-page":"e38768","DOI":"10.1097\/md.0000000000038768","volume":"103","author":"EU Alum","year":"2024","unstructured":"Alum EU, Uti DE, Ugwu OP, et al. Toward a cure - Advancing hiv\/aids treatment modalities beyond antiretroviral therapy: A review. Med (Baltim). 2024;103(27):e38768. https:\/\/doi.org\/10.1097\/md.0000000000038768.","journal-title":"Med (Baltim)"},{"issue":"1","key":"1253_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/qad.0000000000001300","volume":"31","author":"S Gianella","year":"2017","unstructured":"Gianella S, Taylor J, Brown TR, et al. Can research at the end of life be a useful tool to advance HIV. cure? Aids. 2017;31(1):1\u20134. https:\/\/doi.org\/10.1097\/qad.0000000000001300.","journal-title":"cure? Aids"},{"issue":"2","key":"1253_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/qad.0000000000003754","volume":"38","author":"SO Ndukwe","year":"2024","unstructured":"Ndukwe SO, Patel H, Shelton B, et al. People with HIV at the end-of-life and their next-of-kin\/loved ones are willing to participate in interventional HIV cure-related research. Aids. 2024;38(2):235\u201343. https:\/\/doi.org\/10.1097\/qad.0000000000003754.","journal-title":"Aids"},{"issue":"6","key":"1253_CR12","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.jpainsymman.2013.07.004","volume":"47","author":"AC Enzinger","year":"2014","unstructured":"Enzinger AC, Zhang B, Weeks JC, et al. Clinical trial participation as part of end-of-life cancer care: associations with medical care and quality of life near death. J Pain Symptom Manage. 2014;47(6):1078\u201390. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.07.004.","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"1253_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.7326\/0003-4819-156-3-201202070-00008","volume":"156","author":"JW Mack","year":"2012","unstructured":"Mack JW, Cronin A, Taback N, et al. End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med. 2012;156(3):204\u201310. https:\/\/doi.org\/10.7326\/0003-4819-156-3-201202070-00008.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1253_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.7861\/clinmedicine.19-4-306","volume":"19","author":"C Chu","year":"2019","unstructured":"Chu C, White N, Stone P. Prognostication in palliative care. Clin Med (Lond). 2019;19(4):306\u201310. https:\/\/doi.org\/10.7861\/clinmedicine.19-4-306.","journal-title":"Clin Med (Lond)"},{"issue":"5","key":"1253_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/medethics-2021-107512","volume":"49","author":"J Kanazawa","year":"2023","unstructured":"Kanazawa J, Rawlings SA, Hendrickx S, et al. Lessons learned from the last gift study: ethical and practical challenges faced while conducting HIV cure-related research at the end of life. J Med Ethics. 2023;49(5):305\u201310. https:\/\/doi.org\/10.1136\/medethics-2021-107512.","journal-title":"J Med Ethics"},{"issue":"1","key":"1253_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12910-021-00651-1","volume":"22","author":"K Dub\u00e9","year":"2021","unstructured":"Dub\u00e9 K, Kanazawa J, Taylor J, et al. Ethics of HIV cure research: an unfinished agenda. BMC Med Ethics. 2021;22(1):83. https:\/\/doi.org\/10.1186\/s12910-021-00651-1.","journal-title":"BMC Med Ethics"},{"issue":"1","key":"1253_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12904-022-00964-x","volume":"21","author":"M DeCamp","year":"2022","unstructured":"DeCamp M, Alasmar A, Fischer S, et al. Meeting ethical challenges with authenticity when engaging patients and families in end-of-life and palliative care research: a qualitative study. BMC Palliat Care. 2022;21(1):74. https:\/\/doi.org\/10.1186\/s12904-022-00964-x.","journal-title":"BMC Palliat Care"},{"issue":"1","key":"1253_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cei.12814","volume":"187","author":"M Nasi","year":"2017","unstructured":"Nasi M, De Biasi S, Gibellini L, et al. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol. 2017;187(1):44\u201352. https:\/\/doi.org\/10.1111\/cei.12814.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"1253_CR19","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/circresaha.124.323948","volume":"134","author":"K McCutcheon","year":"2024","unstructured":"McCutcheon K, Nqebelele U, Murray L, et al. Cardiac and renal comorbidities in aging people living with HIV. Circ Res. 2024;134(11):1636\u201360. https:\/\/doi.org\/10.1161\/circresaha.124.323948.","journal-title":"Circ Res"},{"issue":"1","key":"1253_CR20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1186\/s12877-022-03477-7","volume":"22","author":"DS Kehler","year":"2022","unstructured":"Kehler DS, Milic J, Guaraldi G, et al. Frailty in older people living with HIV: current status and clinical management. BMC Geriatr. 2022;22(1):919. https:\/\/doi.org\/10.1186\/s12877-022-03477-7.","journal-title":"BMC Geriatr"},{"key":"1253_CR21","doi-asserted-by":"publisher","unstructured":"Shiau S, Bender AA, O\u2019Halloran JA et al. The current state of HIV and aging: findings presented at the 10th International workshop on HIV and aging. AIDS Res Hum Retroviruses. 2020;36(12):973\u2013981. https:\/\/doi.org\/10.1089\/aid.2020.0128","DOI":"10.1089\/aid.2020.0128"},{"issue":"1","key":"1253_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12910-018-0321-2","volume":"19","author":"K Dub\u00e9","year":"2018","unstructured":"Dub\u00e9 K, Gianella S, Concha-Garcia S, et al. Ethical considerations for HIV cure-related research at the end of life. BMC Med Ethics. 2018;19(1):83. https:\/\/doi.org\/10.1186\/s12910-018-0321-2.","journal-title":"BMC Med Ethics"},{"issue":"2","key":"1253_CR23","doi-asserted-by":"publisher","first-page":"100328","DOI":"10.1016\/j.jve.2023.100328","volume":"9","author":"K Dub\u00e9","year":"2023","unstructured":"Dub\u00e9 K, Shelton B, Patel H, et al. Perceived risks and benefits of enrolling people with HIV at the end of life in cure research in Southern california, united States. J Virus Erad. 2023;9(2):100328. https:\/\/doi.org\/10.1016\/j.jve.2023.100328.","journal-title":"J Virus Erad"},{"issue":"1","key":"1253_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20411\/pai.v8i1.583","volume":"8","author":"K Dub\u00e9","year":"2023","unstructured":"Dub\u00e9 K, Villa TJ, Taylor J, et al. A Community-Driven framework to prioritize the use of donated human biological materials in the context of HIV Cure-Related research at the end of life. Pathog Immun. 2023;8(1):1\u201316. https:\/\/doi.org\/10.20411\/pai.v8i1.583.","journal-title":"Pathog Immun"},{"issue":"1","key":"1253_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12910-022-00741-8","volume":"23","author":"J Kanazawa","year":"2022","unstructured":"Kanazawa J, Gianella S, Concha-Garcia S, et al. Ethical and practical considerations for HIV cure-related research at the end-of-life: a qualitative interview and focus group study in the united States. BMC Med Ethics. 2022;23(1):2. https:\/\/doi.org\/10.1186\/s12910-022-00741-8.","journal-title":"BMC Med Ethics"},{"issue":"1","key":"1253_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1556264617734061","volume":"13","author":"K Dub\u00e9","year":"2018","unstructured":"Dub\u00e9 K, Dee L, Evans D, et al. Perceptions of equipoise, Risk-Benefit ratios, and otherwise healthy volunteers in the context of Early-Phase HIV cure research in the united states: A qualitative inquiry. J Empir Res Hum Res Ethics. 2018;13(1):3\u201317. https:\/\/doi.org\/10.1177\/1556264617734061.","journal-title":"J Empir Res Hum Res Ethics"},{"issue":"11","key":"1253_CR27","doi-asserted-by":"publisher","first-page":"e0242420","DOI":"10.1371\/journal.pone.0242420","volume":"15","author":"KE Perry","year":"2020","unstructured":"Perry KE, Taylor J, Patel H, et al. [It] is now my responsibility to fulfill that wish: clinical and rapid autopsy staff members\u2019 experiences and perceptions of HIV reservoir research at the end of life. PLoS ONE. 2020;15(11):e0242420. https:\/\/doi.org\/10.1371\/journal.pone.0242420.","journal-title":"PLoS ONE"},{"issue":"4","key":"1253_CR28","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1172\/jci134815","volume":"130","author":"A Chaillon","year":"2020","unstructured":"Chaillon A, Gianella S, Dellicour S, et al. HIV persists throughout deep tissues with repopulation from multiple anatomical sources. J Clin Invest. 2020;130(4):1699\u2013712. https:\/\/doi.org\/10.1172\/jci134815.","journal-title":"J Clin Invest"},{"key":"1253_CR29","doi-asserted-by":"publisher","unstructured":"Tang Y, Chaillon A, Gianella S, et al. Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy. J Clin Invest. 2023;133(12). https:\/\/doi.org\/10.1172\/jci167417.","DOI":"10.1172\/jci167417"},{"key":"1253_CR30","doi-asserted-by":"publisher","unstructured":"Moranguinho I, Valente ST. Block-and-lock: new horizons for a cure for HIV-1. Viruses. 2020;12(12). https:\/\/doi.org\/10.3390\/v12121443.","DOI":"10.3390\/v12121443"},{"key":"1253_CR31","doi-asserted-by":"publisher","unstructured":"Vargas B, Sluis-Cremer N. Toward a functional cure for HIV-1 infection: the block and lock therapeutic approach. Front Virol. 2022;2(917941). https:\/\/doi.org\/10.3389\/fviro.2022.917941.","DOI":"10.3389\/fviro.2022.917941"},{"issue":"6","key":"1253_CR32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41579-024-01010-8","volume":"22","author":"M Armani-Tourret","year":"2024","unstructured":"Armani-Tourret M, Bone B, Tan TS, et al. Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure. Nat Rev Microbiol. 2024;22(6):328\u201344. https:\/\/doi.org\/10.1038\/s41579-024-01010-8.","journal-title":"Nat Rev Microbiol"},{"issue":"3\u20134","key":"1253_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41434-023-00413-1","volume":"31","author":"S Klinnert","year":"2024","unstructured":"Klinnert S, Schenkel CD, Freitag PC, et al. Targeted shock-and-kill HIV-1 gene therapy approach combining CRISPR activation, suicide gene tBid and retargeted adenovirus delivery. Gene Ther. 2024;31(3\u20134):74\u201384. https:\/\/doi.org\/10.1038\/s41434-023-00413-1.","journal-title":"Gene Ther"},{"issue":"1","key":"1253_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12981-022-00483-y","volume":"19","author":"R Bhowmik","year":"2022","unstructured":"Bhowmik R, Chaubey B. CRISPR\/Cas9: a tool to eradicate HIV-1. AIDS Res Ther. 2022;19(1):58. https:\/\/doi.org\/10.1186\/s12981-022-00483-y.","journal-title":"AIDS Res Ther"},{"key":"1253_CR35","doi-asserted-by":"publisher","unstructured":"Akdeniz M, Yard\u0131mc\u0131 B, Kavukcu E. Ethical considerations at the end-of-life care. SAGE Open Med. 2021;9(20503121211000918). https:\/\/doi.org\/10.1177\/20503121211000918.","DOI":"10.1177\/20503121211000918"},{"issue":"2","key":"1253_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/02692163221137105","volume":"37","author":"GM Yang","year":"2023","unstructured":"Yang GM, Ong WY, Tan J, et al. Motivations and experiences of patients with advanced cancer participating in phase 1 clinical trials: A qualitative study. Palliat Med. 2023;37(2):257\u201364. https:\/\/doi.org\/10.1177\/02692163221137105.","journal-title":"Palliat Med"},{"issue":"3","key":"1253_CR37","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3390\/nursrep14030177","volume":"14","author":"C Tim\u00f3teo","year":"2024","unstructured":"Tim\u00f3teo C, Vitorino J, Ali AM, et al. Legacy in End-of-Life care: A concept analysis. Nurs Rep. 2024;14(3):2385\u201397. https:\/\/doi.org\/10.3390\/nursrep14030177.","journal-title":"Nurs Rep"},{"issue":"4","key":"1253_CR38","doi-asserted-by":"publisher","first-page":"100008","DOI":"10.1016\/j.jve.2020.100008","volume":"6","author":"K Dub\u00e9","year":"2020","unstructured":"Dub\u00e9 K, Perry KE, Mathur K, et al. Altruism: scoping review of the literature and future directions for HIV cure-related research. J Virus Erad. 2020;6(4):100008. https:\/\/doi.org\/10.1016\/j.jve.2020.100008.","journal-title":"J Virus Erad"},{"issue":"1","key":"1253_CR39","doi-asserted-by":"publisher","first-page":"2455917","DOI":"10.1080\/25787489.2025.2455917","volume":"26","author":"D Mthimkhulu","year":"2025","unstructured":"Mthimkhulu D, Dong KL, Ngcobo MW, et al. It is scary to pause treatment\u2019: perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in durban, South Africa. HIV Res Clin Pract. 2025;26(1):2455917. https:\/\/doi.org\/10.1080\/25787489.2025.2455917.","journal-title":"HIV Res Clin Pract"},{"issue":"5","key":"1253_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11904-021-00569-8","volume":"18","author":"L Zheng","year":"2021","unstructured":"Zheng L, Tierney C, Bosch RJ. Analytical treatment interruption in HIV trials: statistical and study design considerations. Curr HIV\/AIDS Rep. 2021;18(5):475\u201382. https:\/\/doi.org\/10.1007\/s11904-021-00569-8.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"8","key":"1253_CR41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1089\/aid.2023.0105","volume":"40","author":"K Dub\u00e9","year":"2024","unstructured":"Dub\u00e9 K, Perez-Brumer A, Patel H, et al. This is actually a really unique moment in time: navigating Long-Acting HIV treatment and HIV cure research with analytical treatment Interruptions-A qualitative interview study in the united States. AIDS Res Hum Retroviruses. 2024;40(8):455\u201363. https:\/\/doi.org\/10.1089\/aid.2023.0105.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"1253_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/aid.2017.0067","volume":"34","author":"K Dub\u00e9","year":"2018","unstructured":"Dub\u00e9 K, Evans D, Dee L, et al. We need to deploy them very thoughtfully and carefully: perceptions of analytical treatment interruptions in HIV cure research in the united States-A qualitative inquiry. AIDS Res Hum Retroviruses. 2018;34(1):67\u201379. https:\/\/doi.org\/10.1089\/aid.2017.0067.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"1253_CR43","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1089\/aid.2019.0118","volume":"36","author":"JSY Lau","year":"2020","unstructured":"Lau JSY, Smith MZ, Allan B, et al. Perspectives on analytical treatment interruptions in people living with HIV and their health care providers in the landscape of HIV Cure-Focused studies. AIDS Res Hum Retroviruses. 2020;36(4):260\u20137. https:\/\/doi.org\/10.1089\/aid.2019.0118.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"1253_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qualitative Res Psychol"},{"key":"1253_CR45","doi-asserted-by":"publisher","unstructured":"Ahmed A, Taylor J, Lau R, Lai JC, DeshanDiunugala S, Louella M, Villa TJ, Freshwater W, Averitt D, Karris M, Berry J, Dee L, Dub\u00e9\u00e9 K. \u201cA curemight help, but it won\u2019t erase it all\u201d: a qualitative study of policy challenges and priorities forlong-term survivors of HIV in the United States. J Int AIDS Soc. 2025;28(7):e70006. https:\/\/doi.org\/10.1002\/jia2.70006. PMID: 40611541; PMCID: PMC12231189.","DOI":"10.1002\/jia2.70006"},{"key":"1253_CR46","doi-asserted-by":"crossref","unstructured":"Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23(4):334\u2013340.","DOI":"10.1002\/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G"},{"key":"1253_CR47","doi-asserted-by":"publisher","unstructured":"Ahmed A, Dujaili JA, Jabeen M, et al. Barriers and enablers for adherence to antiretroviral therapy among people living with HIV\/AIDS in the era of COVID-19: A qualitative study from Pakistan. Front Pharmacol. 2021;12(807446). https:\/\/doi.org\/10.3389\/fphar.2021.807446.","DOI":"10.3389\/fphar.2021.807446"},{"issue":"9","key":"1253_CR48","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388. https:\/\/doi.org\/10.1177\/1049732305276687.","journal-title":"Qual Health Res"},{"key":"1253_CR49","doi-asserted-by":"publisher","unstructured":"Woldemeskel BA, Kwaa AK, Blankson JN. Viral reservoirs in elite controllers of HIV-1 infection: implications for HIV cure strategies. EBioMedicine. 2020;62(103118). https:\/\/doi.org\/10.1016\/j.ebiom.2020.103118.","DOI":"10.1016\/j.ebiom.2020.103118"},{"key":"1253_CR50","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2024.0254","author":"S Meanley","year":"2025","unstructured":"Meanley S, Rodriguez Garcia L, Lisha NE, et al. Exploring stigma and Self-Image: Mixed-methods insights from HIV cure-related research participants undergoing analytical treatment interruptions. AIDS Patient Care STDS. 2025. https:\/\/doi.org\/10.1089\/apc.2024.0254.","journal-title":"AIDS Patient Care STDS"},{"issue":"11","key":"1253_CR51","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s10461-023-04095-z","volume":"27","author":"MAJ Noorman","year":"2023","unstructured":"Noorman MAJ, de Wit JBF, Marcos TA, et al. The importance of social engagement in the development of an HIV cure: A systematic review of stakeholder perspectives. AIDS Behav. 2023;27(11):3789\u2013812. https:\/\/doi.org\/10.1007\/s10461-023-04095-z.","journal-title":"AIDS Behav"},{"issue":"1","key":"1253_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12981-021-00401-8","volume":"18","author":"K Dub\u00e9","year":"2021","unstructured":"Dub\u00e9 K, Kanazawa J, Dee L, et al. Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the united States. AIDS Res Ther. 2021;18(1):75. https:\/\/doi.org\/10.1186\/s12981-021-00401-8.","journal-title":"AIDS Res Ther"},{"issue":"4","key":"1253_CR53","doi-asserted-by":"publisher","first-page":"100360","DOI":"10.1016\/j.jve.2023.100360","volume":"9","author":"MJ Lee","year":"2023","unstructured":"Lee MJ, Godakandaarachchi P, Collins S, et al. Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the united Kingdom. J Virus Erad. 2023;9(4):100360. https:\/\/doi.org\/10.1016\/j.jve.2023.100360.","journal-title":"J Virus Erad"},{"key":"1253_CR54","doi-asserted-by":"publisher","unstructured":"Ait-Ammar A, Kula A, Darcis G, et al. Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs. Front Microbiol. 2019;10(3060). https:\/\/doi.org\/10.3389\/fmicb.2019.03060.","DOI":"10.3389\/fmicb.2019.03060"},{"key":"1253_CR55","doi-asserted-by":"publisher","unstructured":"Schriek AI, Aldon YLT, van Gils MJ, et al. Next-generation bNAbs for HIV-1 cure strategies. Antiviral Res. 2024;222(105788). https:\/\/doi.org\/10.1016\/j.antiviral.2023.105788.","DOI":"10.1016\/j.antiviral.2023.105788"},{"issue":"4","key":"1253_CR56","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/coh.0000000000000799","volume":"18","author":"LL Vrignaud","year":"2023","unstructured":"Vrignaud LL, Schwartz O, Bruel T. Polyfunctionality of broadly neutralizing HIV-1 antibodies. Curr Opin HIV AIDS. 2023;18(4):178\u201383. https:\/\/doi.org\/10.1097\/coh.0000000000000799.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"1253_CR57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/coh.0000000000000600","volume":"15","author":"M Caskey","year":"2020","unstructured":"Caskey M. Broadly neutralizing antibodies for the treatment and prevention of HIV infection. Curr Opin HIV AIDS. 2020;15(1):49\u201355. https:\/\/doi.org\/10.1097\/coh.0000000000000600.","journal-title":"Curr Opin HIV AIDS"},{"issue":"7751","key":"1253_CR58","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta RK, Abdul-Jawad S, McCoy LE, et al. HIV-1 remission following CCR5\u220632\/\u220632 Haematopoietic stem-cell transplantation. Nature. 2019;568(7751):244\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1027-4.","journal-title":"Nature"},{"issue":"1","key":"1253_CR59","doi-asserted-by":"publisher","first-page":"2312318","DOI":"10.1080\/25787489.2024.2312318","volume":"25","author":"K Dub\u00e9","year":"2024","unstructured":"Dub\u00e9 K, Ndukwe SO, Korolkova A, et al. Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San francisco, united States. HIV Res Clin Pract. 2024;25(1):2312318.","journal-title":"HIV Res Clin Pract"},{"issue":"1","key":"1253_CR60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/23294515.2015.1034381","volume":"7","author":"CM Ulrich","year":"2016","unstructured":"Ulrich CM, Ratcliffe SJ, Wallen GR, et al. Cancer clinical trial participants\u2019 assessment of risk and benefit. AJOB Empir Bioeth. 2016;7(1):8\u201316. https:\/\/doi.org\/10.1080\/23294515.2015.1034381.","journal-title":"AJOB Empir Bioeth"},{"issue":"4","key":"1253_CR61","doi-asserted-by":"publisher","first-page":"880","DOI":"10.21037\/apm-23-550","volume":"13","author":"PC Tamsukhin","year":"2024","unstructured":"Tamsukhin PC, Bernardo RM, Eti S. Palliative care considerations for the older adults with HIV\/AIDS: a clinical practice review. Ann Palliat Med. 2024;13(4):880\u201392. https:\/\/doi.org\/10.21037\/apm-23-550.","journal-title":"Ann Palliat Med"},{"issue":"1","key":"1253_CR62","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/njh.0000000000000818","volume":"24","author":"SL Hurley","year":"2022","unstructured":"Hurley SL, DeSanto-Madeya S, Fortney CA, et al. Building strong Clinician-Researcher collaborations for successful hospice and palliative care research. J Hosp Palliat Nurs. 2022;24(1):64\u20139. https:\/\/doi.org\/10.1097\/njh.0000000000000818.","journal-title":"J Hosp Palliat Nurs"},{"issue":"2","key":"1253_CR63","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/jco.22.00358","volume":"41","author":"S Fu","year":"2023","unstructured":"Fu S, Gerber DE, Beg MS. Decentralized clinical trials in oncology: are we ready for a Virtual-First paradigm? J Clin Oncol. 2023;41(2):181\u20135. https:\/\/doi.org\/10.1200\/jco.22.00358.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1253_CR64","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1017\/cts.2024.3","volume":"8","author":"MR Cummins","year":"2024","unstructured":"Cummins MR, Soni H, Ivanova J, et al. Narrative review of telemedicine applications in decentralized research. J Clin Transl Sci. 2024;8(1):e30. https:\/\/doi.org\/10.1017\/cts.2024.3.","journal-title":"J Clin Transl Sci"},{"issue":"9","key":"1253_CR65","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41592-024-02320-8","volume":"21","author":"JE Lunshof","year":"2024","unstructured":"Lunshof JE, Rijssenbeek J. Collaborative ethics: innovating collaboration between ethicists and life scientists. Nat Methods. 2024;21(9):1571\u20134. https:\/\/doi.org\/10.1038\/s41592-024-02320-8.","journal-title":"Nat Methods"}],"container-title":["BMC Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12910-025-01253-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12910-025-01253-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12910-025-01253-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:15:43Z","timestamp":1757448943000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedethics.biomedcentral.com\/articles\/10.1186\/s12910-025-01253-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1253"],"URL":"https:\/\/doi.org\/10.1186\/s12910-025-01253-x","relation":{},"ISSN":["1472-6939"],"issn-type":[{"value":"1472-6939","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with all applicable ethical guidelines and regulatory standards, including the U.S. Code of Federal Regulations and the Declaration of Helsinki. The UCSD IRB granted approval for the study (IRB #808882). Prior to participating in interviews, individuals were provided with an informed consent document. Their verbal consent was captured during the interview process, in compliance with IRB approval. To ensure participant confidentiality, all study-related materials, including interview transcripts, were de-identified, and the original audio recordings were securely deleted after the transcription quality was verified.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.D. provides advisory services to Gilead Sciences, Inc., AbbVie, Inc. and Viiv Healthcare, Inc. All other authors have no interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}